India's high court has waived a waiting period for Sun Pharmaceutical to complete its $4 billion acquisition of Ranbaxy Laboratories. The merger is expected to be completed soon, which will set into motion Sun's pledge to reform manufacturing at Ranbaxy. Four of Ranbaxy's FDA-approved manufacturing facilities in India are banned from shipping to the U.S. market because of data integrity and quality issues. Story | More